Journal of eISSN: 2373-633X JCPCR

Cancer Prevention & Current Research
Volume 1 Issue 3 - 2014
Trojan Horse, Nanomedicine and Oncology
Bruno De Lema Larre*
High Complexity Foundation, Spain
Received: October 29, 2014| Published: December 20, 2014
*Corresponding author: De Lema Bruno, High Complexity Foundation, Pereira, Barcelona, Spain, Email: @
Citation: Larre BDL (2014) Trojan Horse, Nanomedicine and Oncology. J Cancer Prev Curr Res 1(3): 00020. DOI: 10.15406/jcpcr.2014.01.00020


Our world is increasingly miniaturized. Nanotechnology helps this goal. The advancement of nanoscience is undeniable and there is talk that nanoscience will be the second industrial revolution. One of these resources is nanodrugs. These are nanoparticles that carry drugs to specific target cells. Research in this area is of special interest in oncology.
Nanodrug is designed as an element that must have as properties:
I. Affect solely to the target cell in this case neoplastic cells
II. Not affect or destroy healthy cells
III. Not immunologically reactive therefore not arouse an immune reaction against nanoparticles Once the nanodrug comes to cancer cell, it is able to release its contents and meet the objective of destroying the tumor cell, although the theory is simple. Nanodrugs must overcome complex difficulties. First of all must be transported through the blood stream, they circumvent hepatic metabolism and renal excretion, as well as being "silent immune" and finally break through to the neoplastic cell to deposit their contents and destroy the tumor cell and no another. The idea is basically the Trojan horse (Figure 1). A structure apparently without destructive capacity, its interior contains the components necessary to do otherwise. Destroy a target. Doing it stealthily and unexpected. What it is clear that the oncology will not be equal when nanodrugs more frequent, yet, we finish building this Trojan horse.
Figure 1:Trojan horse.
© 2014-2019 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy